Denali Therapeutics (DNLI) Interest Coverage Ratio: History & Chart

Denali Therapeutics Inc.(DNLI)

Biotechnology · South San Francisco, CA

$19.23-0.68 (-3.42%)

Delayed quote: Oct 6, 2026, 10:10 AM EDT

About Denali Therapeutics Inc.

Denali Therapeutics Inc. is a biopharmaceutical firm, founded in 2013 and based in South San Francisco, California, which focuses on identifying and advancing treatments for neurodegenerative conditions within the United States. The company, initially known as SPR Pharma Inc. until its renaming in March 2015, possesses a robust development pipeline. This includes BIIB122/DNL151, a small molecule inhibitor targeting leucine-rich repeat kinase 2 (LRRK2), currently in Phase 1 and Phase 1b clinical trials for Parkinson's disease. Another candidate, DNL310, is progressing through Phase 1/2 clinical studies for Hunter syndrome. For amyotrophic lateral sclerosis (ALS), DNL343 is in Phase 1 trials, while AR443820/DNL788 has successfully concluded its Phase 1 clinical trial for ALS, multiple sclerosis (MS), and Alzheimer's disease. Furthermore, SAR443122/DNL758 is undergoing Phase 2 clinical trials for cutaneous lupus erythematosus. Denali Therapeutics is engaged in extensive collaborative efforts with a range of partners, including Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene. It also maintains a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG to co-develop antisense therapies specifically for neurodegenerative diseases.

South San Francisco, CA

503 employees

www.denalitherapeutics.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Ryan J. Watts

View full financials

NAME	MARKET CAP	INTEREST COVERAGE RATIO	TTM	3Y	5Y
Denali Therapeutics Inc. (DNLI)	$3.05B	N/A	N/A	N/A	N/A
Enliven Therapeutics, Inc. (ELVN)vs ›	$3.09B	N/A	N/A	N/A	N/A
Arcutis Biotherapeutics, Inc. (ARQT)vs ›	$3.04B	-1.01x	N/A	N/A	N/A
Amylyx Pharmaceuticals, Inc. (AMLX)vs ›	$3.01B	N/A	N/A	N/A	N/A
Dyne Therapeutics, Inc. (DYN)vs ›	$2.80B	-75.61x	0.12x	0.12x	0.12x
AtriCure, Inc. (ATRC)vs ›	$2.81B	-0.59x	11.23x	11.23x	11.23x
TransMedics Group, Inc. (TMDX)vs ›	$2.83B	7.88x	5.24x	5.24x	5.24x
Acadia Pharmaceuticals Inc. (ACAD)vs ›	$3.40B	N/A	407.95x	407.95x	407.95x
MBX Biosciences, Inc. Common Stock (MBX)vs ›	$2.74B	N/A	N/A	N/A	N/A
Celcuity Inc. (CELC)vs ›	$3.45B	-10.04x	N/A	N/A	N/A

NAME

MARKET CAP

INTEREST COVERAGE RATIO

TTM

Denali Therapeutics Inc. (DNLI)

$3.05B

N/A

Enliven Therapeutics, Inc. (ELVN)vs ›

$3.09B

N/A

Arcutis Biotherapeutics, Inc. (ARQT)vs ›

$3.04B